Roche Holding is challenging Pfizer in the effort to develop a drug focusing on the "good" type of cholesterol by licensing the JTT-705 experimental drug from Japan Tobacco. Pfizer's version is further along in the clinical-trial stage, but Roche plans to use the Japanese product to compete with Pfizer in the market for a cholesteryl ester transfer protein inhibitor.

Full Story:

Related Summaries